Infectious disease test kit SOBC-HP

for cancersfor genetic mutationsfor gastrointestinal diseases

The FIRST national approved H. pylori 23s rRNA gene mutation detection kit from China. It can detect Hp infection and 23s rRNA gene mutation to clarithromycin, providing properest reference for clarithromycin use and Hp infection treatment. In H. Pylori eradication, first time treatment should be paid the highest attention. The key point in treatment is to choose the right antibiotics. Clarithromycin triple-therapy is usually the first-line method used worldwide because of its higher safety, less side effects. The H.Pylori eradication rate will reach more than 99% when used with other drugs in the first treatment if the clarithromycin resistance is tested sensitive. Intended Use This kit is designed for in vitro qualitative detection of three point mutations--A2142G, A2143G and A2142C- in two polymorphic sites of the H. pylori 23S rRNA gene in gastric mucosal tissue samples from patients with H. pylori infection. It's used as clinical auxiliary diagnosis of H. pylori clarithromycin resistance and reference for clinicians to assess the HP resistance properties in individuals. The kit is suitable for H. pylori infected patients who are required clinically to do HP drug-resistance diagnosis with their gastric mucosal tissue samples. Characteristics 1. It can differentiate gene mutation types. 2. Predicting clarithromycin drug-resistance, providing prescription reference and help to guide clinical use of clarithromycin. 3. High specificity, high sensitivity, strong anti-interference ability, internal reference gene quality control. 4. First national approved Hp gene mutation detection kit from China.